Intravacc announced that it has initiated a Phase 1 trial of Avacc 10 intranasal SARS-CoV-2 subunit vaccine, which the company is developing as a booster. Avacc 10 is based on the same outer membrane vesicles (OMV) technology as the company’s intranasal vaccines against gonorrhea and betacoronavirus vaccines. Intravacc had announced in June 2020 that it would develop an intranasal vaccine against COVID-19 in partnership with Wageningen Bioveterinary Research and Utrecht University, and the company announced positive pre-clinical data for its intranasal SARS-CoV-2 candidate vaccine in April 2021.
The Phase 1 study is expected to enroll 36 healthy volunteers who will receive either a low dose of the vaccine or a high dose, with each group getting a second dose three weeks after the first. Observation of the volunteers will continue for 6 months, and interim results are expected at the end of the first quarter, 2023.
Intravacc CEO Jan Groen commented, “This is a very important milestone in the development of our intranasal OMV-based vaccine. We strongly believe that intranasal vaccines offer major advantages over injectable vaccines, and we are excited to take our vaccine concept to the next stage, supporting our CDMO business.”
Read the Intravacc press release.
